Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Boulding Mark Elliott, holds the title of EXEC. VP AND CLO at PTC THERAPEUTICS, INC..
On 2026-11-16, the insider transacted 5,624 shares.The shares were transacted at a weighted average price of $43.79 per share, resulting in a total market-relevant value of $246K.
Boulding Mark Elliott (EXEC. VP AND CLO) sold $246K of $PTCT
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.